Non-small Cell Lung Cancer Metastatic Clinical Trial
Official title:
A Phase II Trial of Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.
Patients with advanced cancers who have pleural effusion, especially those requiring pleural evacuation, experienced poorer survival when treated with immunotherapy. The pleura also acts as a natural barrier that can limit the penetration of immune checkpoint inhibitors. In this multicenter phase 2 study, the preliminary efficacy and toxicity of intrapleural instillation of the nivolumab in patients with immune-sensitive metastatic cancers will be accessed.
Patients ≥18 years old who have large volume of pleural effusion, required evacuation, and received systemic therapy with a checkpoint inhibitor (monotherapy or combination with another checkpoint inhibitor) for metastatic cancers (renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) will be eligible. Drainage followed by nivolumab (40 mg, single intrapleural instillation) will be performed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01523340 -
A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response
|
||
| Recruiting |
NCT03956641 -
Evolution of the Physical Condition in Treated Cancer Patients
|
N/A | |
| Active, not recruiting |
NCT02035683 -
PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy
|
N/A | |
| Completed |
NCT01848613 -
Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC
|
Phase 4 | |
| Suspended |
NCT01320501 -
Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
|
Phase 4 | |
| Terminated |
NCT01471964 -
Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06127940 -
K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation
|
Phase 1 | |
| Terminated |
NCT04069936 -
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
|
Phase 2 | |
| Terminated |
NCT03445000 -
ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT03386929 -
Survival Prolongation by Rationale Innovative Genomics
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02922764 -
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
|
Phase 1 | |
| Terminated |
NCT01574300 -
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
|
||
| Active, not recruiting |
NCT04646824 -
Almonertinib With Chemotherapy in mEGFR NSCLC
|
Phase 2 | |
| Completed |
NCT01966003 -
Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT03656094 -
Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors
|
Phase 2 | |
| Terminated |
NCT01348126 -
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03469960 -
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr
|
Phase 3 | |
| Recruiting |
NCT05919264 -
FOG-001 in Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT04793815 -
Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)
|
N/A | |
| Terminated |
NCT01380795 -
Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas
|
Early Phase 1 |